NOVO NORDISK
LIVE

Serial Number

79290058

Owner

Novo Nordisk A/S

Attorney

Alexander Reid

Filing Date

Apr 3, 2020

Add to watchlist:

No watchlists yet
View on USPTO

NOVO NORDISK Trademark

Serial Number: 79290058 • Registration: 6317854

NOVO NORDISK is a trademark filed by Novo Nordisk A/S on April 3, 2020. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 9 (Computers & Electronics), Class 10 (Medical Apparatus), Class 41 (Education & Entertainment), Class 42 (Computer & Scientific), Class 44 (Medical Services). The application is currently registered and active.

Owner Contact Info

Novo Nordisk A/S (13 trademarks)

Novo Alllé

Entity Type: 65

Trademark Details

Filing Date

April 3, 2020

Registration Date

April 13, 2021

Published for Opposition

January 26, 2021

Goods & Services

Chemical preparations for use in industry; chemical additives for use in the manufacture of pharmaceuticals, cosmetics, hair lotions, disinfectants; chemical diagnostic reagents for industrial use, for non-medical and non-veterinary purposes; chemical preparations for use in the oil industry

downloadable electronic publications, namely, leaflets, books, booklets, handouts, magazines, as well as medical, instructional and teaching material in the field of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; downloadable electronic publications featuring electronic reports containing results from clinical trials and studies in the field of prevention and treatment of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; downloadable software applications for use with mobile devices for monitoring and management of medical data related to diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; computer hardware and downloadable software, for use with medical injection devices for collecting, transmitting, and displaying medical data; downloadable medical software for the management of medical data related to diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; downloadable software as a medical device, namely, software used in connection with medical devices to manage treatment of haemostasis management and for the treatment of sickle cell disease, brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cells for medical purposes

Providing scientific research information in the field of diabetes, obesity, haemostasis management, treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; providing temporary use of online non-downloadable software featuring technology that enables users to record, track, and generate reports regarding the condition, treatment and the management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment

Pharmaceutical preparations for the treatment of diabetes and obesity; pharmaceutical preparations for haemostasis management and for the treatment of sickle cell disease; pharmaceutical preparations for the treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease; pharmaceutical preparations for hormone therapy and stem cells for medical purposes; drug delivery devices containing pharmaceutical preparations for haemostasis management, pharmaceutical preparations for the treatment of sickle cell disease, brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, pharmaceutical preparations for hormone therapy and stem cells for medical purposes; chemical preparations for use in medical devices, namely, drug delivery agents consisting of compounds that deliver a wide range of pharmaceuticals

Medical and surgical apparatus and instruments, namely, hypodermic syringes and syringe pens; medical apparatus and instruments for reconstitution and injection of pharmaceutical preparations; medical apparatus and instruments, namely, injection devices for administration of pharmaceutical preparations, medical infusion pumps for delivering measured amounts of solutions into the bloodstream over time, infusion pump controllers, adhesive infusion devices for administering drugs; digitally connected medical devices for monitoring the dispensation of pharmaceutical preparations for use in connection with the management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; medical and surgical apparatus and instruments, namely, injection devices for the administration of pharmaceutical preparations and the wireless transmission of medical data in connection with the management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; medical devices, namely, automatic needle insertion devices, protection caps for hypodermic syringes and medical pens; needles for injections; cartridges and carpules for administration of pharmaceutical preparations

Educational services, namely, organizing and conducting educational programmes, coaching and training services for patients and healthcare professionals related to management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; arranging and conducting of educational conferences, congresses, seminars, symposiums and workshops related to the management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment

Providing medical services via websites and mobile apps for the management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment; providing medical information and medical counselling featuring the management of diabetes, obesity, haemostasis management and for the treatment of sickle cell disease, treatment of brain disorders, non-alcoholic steatohepatitis, atherosclerosis, cardiovascular disease, chronic kidney disease, hormone therapy and stem cell treatment

Filing History

CHANGE OF NAME/ADDRESS REC'D FROM IB
Jul 2, 2026 ADCH
FINAL DECISION TRANSACTION PROCESSED BY IB
Aug 15, 2021 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Jul 27, 2021 FICS
FINAL DISPOSITION PROCESSED
Jul 27, 2021 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jul 13, 2021 FICR
REGISTERED-PRINCIPAL REGISTER
Apr 13, 2021 R.PR
NOTIFICATION PROCESSED BY IB
Feb 6, 2021 GPNX
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 26, 2021 NPUB
PUBLISHED FOR OPPOSITION
Jan 26, 2021 PUBO
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jan 13, 2021 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Jan 6, 2021 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 6, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 17, 2020 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 17, 2020 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 17, 2020 CRFA
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 17, 2020 TEME
EXAMINER'S AMENDMENT ENTERED
Dec 17, 2020 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 17, 2020 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 17, 2020 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 17, 2020 CNEA
CORRECTION FROM IB ENTERED - ATTORNEY REVIEW REQUIRED
Dec 9, 2020 CREV
CORRECTION SENT TO IB
Nov 18, 2020 CRSN
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 11, 2020 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 11, 2020 TROA
CORRECTION TRANSACTION RECEIVED FROM IB
Oct 10, 2020 CRCV
REFUSAL PROCESSED BY IB
Sep 27, 2020 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Sep 6, 2020 RFCS
REFUSAL PROCESSED BY MPU
Sep 2, 2020 RFRR
CORRECTION CREATED FOR IB
Sep 1, 2020 CRCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 30, 2020 RFCR
NON-FINAL ACTION WRITTEN
Jul 29, 2020 CNRT
APPLICATION FILING RECEIPT MAILED
Jul 28, 2020 MAFR
ASSIGNED TO EXAMINER
Jul 24, 2020 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jul 24, 2020 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jul 23, 2020 REPR